Member Info for CheeryMike778

I am no expert. It was on my LinkedIn. I remember seeing 600 is 10x cheaper

I don’t know what you mean. I will go back to just reading. Thank you everybody for your reassurance.

Thank you guys. Ai makes it sound like 6000 isn’t as good.

Emi-Le (Servier – ACC)

* ORR: 35.6% overall (46.9% in higher-risk ACC subgroup)

* Median PFS: 7.8 months (mature Phase 1 readout)

* Well-defined ACC population

* Endpoints are fully calculable and stable

⸻

AVA6000 (Avacta – salivary gland cancers)

Phase 1a (~11 patients)

* ORR: very limited numbers (small cohort; early responses only)

* Median PFS: ~9 months (very small n, early signal only)

Phase 1b (expansion cohort – ongoing)

* ORR: ~10% overall response rate reported so far

* Disease control: ~90–92%

* Median PFS: not yet mature / not formally established

⸻

Direct comparison

ORR

* Emi-Le: ~36–47% (strong, consistent response rate in ACC)

* AVA6000: ~10% (early expansion signal, broader population)

👉 Clear advantage:

Emi-Le (significantly higher response rate and more defined dataset)

⸻

PFS

* Emi-Le: 7.8 months (confirmed median)

* AVA6000: ~5–9 month early range, not a final median

👉 Clear advantage:

Emi-Le (because it has a mature, reportable median PFS)

⸻

Overall interpretation (biased toward Emi-Le)

Even allowing for early-stage uncertainty:

Emi-Le is stronger because:

* Higher ORR (~36–47% vs ~10%)

* Mature, reportable PFS (7.8 months)

* Clean ACC-specific dataset

* More statistically reliable Phase 1 readout

⸻

AVA6000 profile right now:

* Lower early ORR (~10%)

* PFS still evolving (no confirmed median in full dataset)

* Data still split across Phase 1a + ongoing Phase 1b expansion

* Potential signal exists, but not yet mature or competitive on headline efficacy metrics

⸻

Bottom line

Based on current available data, Emi-Le shows a stronger and more mature efficacy profile than AVA6000, particularly on ORR and PFS consistency, while AVA6000 remains earlier-stage with a modest (~10%) emerging response rate and immature survival data

Try this link. Thanks mate. They seem to have completely cured one person

https://www.biospace.com/press-releases/promising-phase-1-data-for-serviers-emiltatug-ledadotin-emi-le-in-adenoid-cystic-carcinoma-acc-presented-at-asco-2026

Sorry, I don’t post, so hopefully I’m doing this right. I saw this on LinkedIn, does anyone know whether this salivary gland cancer drug could affect Ava600

AI said Adenoid cystic carcinoma (ACC) is usually a form of salivary gland cancer, with most cases arising in the salivary glands of the head and neck.

Servier’s Emi-Le has reported encouraging Phase 1 data in aggressive ACC:

• ORR: 35.6% overall

• ORR: 46.9% in the higher-risk ACC subgroup

• Disease control rate: 82.2%

• 1 complete response

• Median PFS: 7.8 months

• No Grade 4 or 5 treatment-related adverse events

The data appears strong for a Phase 1 study in ACC and has contributed to the FDA granting Breakthrough Therapy Designation. As ACC is a salivary gland cancer, the results provide further evidence that novel targeted therapies can achieve meaningful clinical activity in this disease area.

https://www.linkedin.com/posts/lowinger_promising-phase-1-data-for-serviers-emiltatug-share-7467280003697704960-7UMl/utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAECYRnoB2lwV_EbQoGVJY06SwaMt06fUdiA